IntegraGen, focused on the development and commercialisation of molecular diagnostic tests for complex diseases, has announced the establishment of a wholly-owned US subsidiary, based in New York
Robert Gottlieb has been appointed as its chief executive officer.
Commenting on the move, Gottlieb said: "It is a pleasure to join IntegraGen as the firm moves toward commercialisation of its first product in the United States.
The company has done an excellent job discovering and patent protecting biomarkers associated with complex diseases and leveraging the expertise of well respected partners.
Based on discussions with researchers and clinicians, IntegraGen is uniquely positioned to deliver molecular diagnostic products that will improve the quality of life for millions of individuals.
In addition to his role as chief executive officer of IntegraGen Inc, Gottlieb, who has been working with IntegraGen for the past five months, also holds the position of VP global sales and marketing for the IntegraGen group, where he has responsibility for sales and marketing of diagnostic testing and counselling services offered through the company's Diabetes Competence Center, in Bonn and the Genetic Research Services business, based in France.
Gottlieb has more than twenty years working experience in the diagnostics and medical device industry with firms including Abbott Laboratories, General Electric, and Becton Dickinson.
Prior to IntegraGen, he was with Roche Diagnostics, where he held a variety of Director level positions.
He obtained his MBA from Temple University, Philadelphia, PA, a BA in biology from LaSalle University, Philadelphia, PA.
Jan Mous, president and CEO of IntegraGen SA, said: "With the incorporation of IntegraGen, the IntegraGen group has made a significant step forward and allows the group to effectively market its genetic testing services into this important market.
"We are very pleased to welcome Rob to the team - his expertise will be critical in helping drive our sales and marketing strategy forward."
